UNLABELLED: Immunization with effective cancer vaccines can offer a much needed adjuvant therapy to fill the treatment gap after liver resection to prevent relapse of hepatocellular carcinoma (HCC). However, current HCC cancer vaccines are mostly based on native shared-self/tumor antigens that are only able to induce weak immune responses. In this study we investigated whether the HCC-associated self/tumor antigen of alpha-fetoprotein (AFP) could be engineered to create an effective vaccine to break immune tolerance and potently activate CD8 T cells to prevent clinically relevant carcinogen-induced autochthonous HCC in mice. We found that the approach of computer-guided methodical epitope-optimization created a highly immunogenic AFP and that immunization with lentivector expressing the epitope-optimized AFP, but not wild-type AFP, potently activated CD8 T cells. Critically, the activated CD8 T cells not only cross-recognized short synthetic wild-type AFP peptides, but also recognized and killed tumor cells expressing wild-type AFP protein. Immunization with lentivector expressing optimized AFP, but not native AFP, completely protected mice from tumor challenge and reduced the incidence of carcinogen-induced autochthonous HCC. In addition, prime-boost immunization with the optimized AFP significantly increased the frequency of AFP-specific memory CD8 T cells in the liver that were highly effective against emerging HCC tumor cells, further enhancing the tumor prevention of carcinogen-induced autochthonous HCC. CONCLUSIONS: Epitope-optimization is required to break immune tolerance and potently activate AFP-specific CD8 T cells, generating effective antitumor effect to prevent clinically relevant carcinogen-induced autochthonous HCC in mice. Our study provides a practical roadmap to develop effective human HCC vaccines that may result in an improved outcome compared to the current HCC vaccines based on wild-type AFP.
UNLABELLED: Immunization with effective cancer vaccines can offer a much needed adjuvant therapy to fill the treatment gap after liver resection to prevent relapse of hepatocellular carcinoma (HCC). However, current HCC cancer vaccines are mostly based on native shared-self/tumor antigens that are only able to induce weak immune responses. In this study we investigated whether the HCC-associated self/tumor antigen of alpha-fetoprotein (AFP) could be engineered to create an effective vaccine to break immune tolerance and potently activate CD8 T cells to prevent clinically relevant carcinogen-induced autochthonous HCC in mice. We found that the approach of computer-guided methodical epitope-optimization created a highly immunogenic AFP and that immunization with lentivector expressing the epitope-optimized AFP, but not wild-type AFP, potently activated CD8 T cells. Critically, the activated CD8 T cells not only cross-recognized short synthetic wild-type AFPpeptides, but also recognized and killed tumor cells expressing wild-type AFP protein. Immunization with lentivector expressing optimized AFP, but not native AFP, completely protected mice from tumor challenge and reduced the incidence of carcinogen-induced autochthonous HCC. In addition, prime-boost immunization with the optimized AFP significantly increased the frequency of AFP-specific memory CD8 T cells in the liver that were highly effective against emerging HCC tumor cells, further enhancing the tumor prevention of carcinogen-induced autochthonous HCC. CONCLUSIONS: Epitope-optimization is required to break immune tolerance and potently activate AFP-specific CD8 T cells, generating effective antitumor effect to prevent clinically relevant carcinogen-induced autochthonous HCC in mice. Our study provides a practical roadmap to develop effective humanHCC vaccines that may result in an improved outcome compared to the current HCC vaccines based on wild-type AFP.
Authors: C M Vollmer; F C Eilber; L H Butterfield; A Ribas; V B Dissette; A Koh; L D Montejo; M C Lee; K J Andrews; W H McBride; J A Glaspy; J S Economou Journal: Cancer Res Date: 1999-07-01 Impact factor: 12.701
Authors: Daniel E Speiser; Petra Baumgaertner; Verena Voelter; Estelle Devevre; Catherine Barbey; Nathalie Rufer; Pedro Romero Journal: Proc Natl Acad Sci U S A Date: 2008-03-04 Impact factor: 11.205
Authors: Yanjun Liu; Yibing Peng; Michael Mi; Jose Guevara-Patino; David H Munn; Ning Fu; Yukai He Journal: J Immunol Date: 2009-05-15 Impact factor: 5.422
Authors: David K Cole; Emily S J Edwards; Katherine K Wynn; Mathew Clement; John J Miles; Kristin Ladell; Julia Ekeruche; Emma Gostick; Katherine J Adams; Ania Skowera; Mark Peakman; Linda Wooldridge; David A Price; Andrew K Sewell Journal: J Immunol Date: 2010-07-16 Impact factor: 5.422
Authors: Sha Wu; Wei Zhu; Yibing Peng; Lan Wang; Yuan Hong; Lei Huang; Dayong Dong; Junping Xie; Todd Merchen; Edward Kruse; Zong Sheng Guo; David Bartlett; Ning Fu; Yukai He Journal: Cancer Immunol Res Date: 2017-08-29 Impact factor: 11.151